Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a written consent form before any trial-related procedures begin.
• Women aged 18 to 80 years old.
• People who are generally well enough to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required).
• People newly diagnosed with certain specific types of uterine (endometrial) cancer confirmed by a tissue or cell sample — including endometrioid, serous, clear cell, undifferentiated, mixed cell, mesonephric, mucinous, intestinal-type mesonephric-like, carcinosarcoma types.
• People with endometrial cancer that has come back locally or spread to a limited number of sites (no more than 5 areas in total), with specific limits on how many spots are present in the liver and lungs.
• People who have at least one tumour area that can be treated with radiotherapy and can be measured according to standard research guidelines.
• People who have tumour tissue available that can be used for biological marker testing.
• People with an expected survival of at least 6 months.
• People whose blood counts, liver function, kidney function, blood clotting, thyroid levels, and heart function all fall within acceptable ranges on tests taken within 7 days before joining (confirm specific values with trial site).
• People whose side effects from any previous cancer treatments have mostly resolved before starting the trial, except for certain ongoing effects such as mild nerve symptoms or hair loss (confirm with trial site).
• Women who could become pregnant must use a medically recognised form of contraception during treatment and for 3 months afterward, must not be breastfeeding, and must have a negative pregnancy test within 7 days before joining.

Who may not be able to join:

• People who have an active autoimmune disease or a history of one (such as autoimmune hepatitis, inflammatory bowel conditions, or autoimmune thyroid problems), with some exceptions such as fully resolved childhood asthma or vitiligo (confirm with trial site).
• People currently taking immune-suppressing medications, including corticosteroids above a certain dose, within 2 weeks before joining.
• People who previously experienced a severe (grade 3 or 4) immune-related reaction from cancer immunotherapy.
• People with poorly controlled heart conditions, such as moderate-to-severe heart failure, unstable chest pain, a recent heart attack, significant heart rhythm problems, or an abnormal heart electrical reading above certain thresholds.
• People with blood clotting problems, a tendency to bleed, or who are currently on blood-thinning or clot-dissolving medications.
• People who received cancer treatments such as radiotherapy, chemotherapy, hormone therapy, surgery, or targeted therapy within 4 weeks (or longer, depending on the drug) before starting the trial, or whose side effects from those treatments have not sufficiently resolved.
• People with significant fluid build-up in body cavities (such as the chest or abdomen) that requires drainage or other procedures to manage.
• People who have had significant coughing up of blood in the 2 months before joining, or who cough up meaningful amounts of blood daily.
• People with known hereditary or acquired bleeding or clotting disorders (such as haemophilia or low platelet conditions).
• People with an active infection or unexplained fever above 38.5°C at the time of screening or before starting treatment.
• People with a history of or current lung scarring, inflammation, or severely reduced lung function.
• People with immune deficiency conditions (such as HIV) or active hepatitis B or C infection based on blood test results.
• People who have taken another experimental drug or received radiotherapy or other local treatments very recently and have not recovered from those effects.
• People with a history of another type of cancer, except for fully treated skin basal cell carcinoma or cervical pre-cancer (carcinoma in situ).
• People who may need other systemic (whole-body) cancer treatments during the study.
• People who have received or are expected to receive a live vaccine within 4 weeks before starting or during the trial.
• People who have other serious conditions — including severe mental health disorders, major abnormal test results, or personal or social circumstances — that the trial team considers could affect safety or the ability to collect reliable data.

Important: Always verify eligibility with the trial site directly before applying.